The majority of the human genome is made of transposable elements, giving rise to interspaced repeats, including Long Interspersed Element-1s (LINE-1s or L1s). L1s are active human DNA parasites involved in genomic diversity and evolution, but can also contribute to genomic instability and diseases. L1s require host factors to complete their life cycles, whereas the host has evolved numerous mechanisms to restrict L1-induced mutagenesis. Restriction mechanisms in somatic cells include methylation of the L1 promoter, anti-viral factors and RNA-mediated processes such as small RNAs. microRNAs (miRNAs or miRs) are small non-coding RNAs that post-transcriptionally repress multiple target genes often found in the same cellular pathways. We have recently established that the interferon-inducible miR-128 function as a novel restriction factor inhibiting L1 mobilization in somatic cells. We have further demonstrated that miR-128 function through a dual mechanism; by directly targeting L1 RNA for degradation and indirectly by inhibiting a cellular co-factor which L1 is dependent on to transpose to new genomic locations (TNPO1).
INTRODUCTION
Long-interspaced nuclear elements-1 (LINE-1 or L1) are the only autonomous transposable elements and account for approximately 17% of the human genome [1] [2] [3] .
Although the majority of L1 encoded in the genome is truncated and inactive, intact and active L1 is ~6 kilobase pairs (kb) in length and contains a 5'UTR, three open-reading frames -ORF1, ORF2 and ORF0 -and a short 3'UTR. The 5'UTR has promoter activity in both the sense and antisense direction [4] [5] [6] . ORF1 encodes a 40 kDa protein with RNA-binding and nucleic acid chaperone activity and ORF2 encodes a 150 kDa protein with endonuclease and reverse transcriptase activities [7] [8] [9] . ORF0 is transcribed in the antisense direction and encodes a protein that enhances L1 retrotransposition, however the exact mechanism remains unknown [10] . L1 mobilizes and replicates via an RNA by a "copy and paste" mechanism via an RNA intermediate [11, 12] . Integration of L1 at new locations in the genome generates mutations that can create new genes or affect gene expression [13, 14] . L1 retrotransposition is associated with a variety of diseases ranging from Hemophilia to cancer and developmental abnormalities [2, [15] [16] [17] [18] .
(ncRNA) may rival that of proteins in regulating multiple genetic pathways [28, 29] . miRs are endogenously encoded 21-24-nucleotide (nt) RNAs that regulate the expression of mRNAs containing complementary sequences. After transcription and processing in the nucleus, the mature miR is loaded onto specific Argonaute (Ago) proteins -referred to as a miR-induced silencing complex (miRISC) -in the cytoplasm. The miRISC then binds to partially complementary mRNA sequences and mediates mRNA degradation and translational [29, 30] . Complementarity between the miR (5' position 2-7) and a mRNA target "seed" site usually results in reduced protein expression through a variety of mechanisms that involve mRNA degradation and translational repression [30, 31] .
We recently established that miR-128 represses the activity of L1 retrotransposons in somatic cells. We described a novel mechanism for this regulation, by which miR-128 binds directly to the ORF2 coding region sequence of L1 RNA resulting in L1 repression [32] . In addition, we have recently expanded the mechanistic studies of miR-128-induced L1 restriction, demonstrating that miR-128 also represses the cellular nuclear import factor Transportin 1 (TNPO1), which we find L1 is dependent on for de novo retrotransposition (Idica et al. in revisions 2017). It is well established that miRs repress multiple cellular mRNAs by binding to homologous target seed sequences; the proteins of these target mRNAs frequently function in the same pathway, suggesting that miRs act to fine-tune specific cellular networks [33] [34] [35] [36] .
In this study, we wished to identify additional cellular targets of miR-128 that may be involved in the L1 retrotransposition pathway. Here we report that miR-128 also represses retrotransposition by targeting a key cellular factor required for L1 retrotransposition, namely hnRNPA1 (heterogenous nuclear ribonucleoprotein A1). hnRNPA1 is one of the most abundant proteins in the nucleus and is expressed in all cell types and tissues [37] . The hnRNPA1 proteins is involved in both DNA and RNA metabolism including genomic stability and telomere binding [38, 39] . hnRNPA1 is bound to poly (A) sequences of RNA on both the cytoplasm and nucleus [40] and accompanies mature transcripts through the Nuclear Pore Complex, supporting its proposed role in mRNA shuttling [41] . The nuclear localization of hnRNPA1 depends on a 38aa long nuclear localization sequence known as M9 [42] [43] [44] , which binds to TNPO1 to mediate shuttling through the nuclear pore complex [39, 45-49]. It has been described that hnRNPA1 interact with L1 ORF1p through an RNA bridge, likely as part of the L1-RNP complex [50] . In this study, we show that miR-128 regulates hnRNPA1 levels and demonstrate that hnRNPA1 is required for efficient L1 replication and de novo retrotransposition. Thus, we have discovered another key player in the L1 life cycle, which is subjected to miR-128 regulation.
RESULTS

Identification of miR-128 targets which function as co-factors for L1 retrotransposition
We have previously demonstrated that miR-128 directly targets L1 RNA and represses de novo retrotransposition and genomic integration in somatic cells [32] .
Furthermore, we recently determined that miR-128 also regulates cellular co-factors, some of which L1 may be dependent on. It has previously been debated whether L1-RNP is only dependent on cell division to access host DNA [51] [52] [53] . However, the hypothesis could not account for how L1 integrates back into the genome in non-dividing cells such as neurons [54] . For this reason we were excited to determine that miR-128 also targets the nuclear import factor Transportin 1 (TNPO1), resulting in reduced nuclear import of L1 Ribonuclear Protein (L1-RNP) complexes (Idica et al. in revisions). However as TNPO1 does not contain a nuclear localization signal (NLS), many questions were left unanswered.
In order to identify additional miR-128 targets involved in the regulation of L1 Figure 1A ).
Interestingly, several members of the hnRNP (heterogenous nuclear ribonucleoprotein) family were identified (hnRNPA1, hnRNPA2B1, hnRNPK, hnRNPL and hnRNPU) as potential miR-128 targets and ORF1p interaction partners ( Figure 1A ). To validate the findings in the primary screen, we generated lentiviruses containing plasmids encoding miR- and a teratoma cell line (Tera-1). miR-128 significantly reduced hnRNPA1 in all but the lung cancer cell line and anti-miR-128 showed substantial enhanced hnRNPA1 levels in all cell lines except the Teratoma cell line ( Figure 2B ). Next we determined that miR-128
overexpressing HeLa cells showed significantly reduced hnRNPA1 protein levels and antimiR-128 significantly enhanced hnRNPA1 protein amounts, relative to miR control HeLa cells, correlating with hnRNPA1 mRNA levels ( Figure 2C ). We finally validated that miR-128 regulates hnRNPA1 protein levels in additional 3 cancer cell lines (A549 (lung cancer), SW620 (colon cancer) and PANC1 (pancreatic cancer)). Together, these results show that miR-128 regulates hnRNPA1 mRNA and protein levels in multiple cell types.
miR-128 binds directly to the CDS of hnRNPA1 mRNA
We next wished to determine if hnRNPA1 mRNA is a direct target of miR-128.
When performing bioinformatics analyses of potential miR-128 binding sites in hnRNPA1
mRNA, we identified one potential 7-mer seed site in the coding DNA sequence (CDS) ( Figure 3A ). The CDS sequence of hnRNPA1 including the seed site was cloned into a miRbinding site luciferase reporter construct. As a positive control construct, a 23nt with perfect complementarity was generated as well. HeLa cells were co-transfected with the hnRNPA1 one of the binding site-encoding plasmid and either mature miR-128 or miR control mimics.
Luciferase activity was significantly reduced in cells co-transfected with miR-128 and the plasmid encoding the hnRNPA1 binding site relative to those co-transfected with the miR control mimic and hnRNPA1 binding site plasmid ( Figure 3B , left panel). These results indicate that miR-128 binds to the seed site located in the CDS of hnRNPA1. To further characterize the specificity of miR-128 binding to the seed site in hnRNPA1, a mutated seed site was generated and cloned into the miR-binding site luciferase reporter plasmid ( Figure   3A ). HeLa cells were co-transfected with one of the binding site-encoding plasmid (WT, seed mutant or positive control) and either mature miR-128 or miR control mimics. anti-miR-128 input samples, the relative fraction of Argonaute-bound hnRNPA1 mRNA in IP samples were found to be more significantly reduced, relative to miR-128 samples ( Figure   3C , top right panel "corrected"). miR-128 did not reduce GAPDH mRNA amounts or immuno-purified GAPDH mRNA ( Figure 3D ). These data combined, suggests that induced amounts of miR-128 result in enrichment of hnRNPA1 mRNA bound to Argonaute complexes by a direct interaction with the seed sequence in the CDS of hnRNPA1 mRNA.
L1 retrotransposition is dependent on hnRNPA1
hnRNPA1 is a known binding partner of L1 ORF1p [50] and TNPO1 (Idica et al. in revisions) suggesting a possible role for hnRNPA1 in the L1 retrotransposition life cycle. We first wished to determine whether hnRNPA1 is required for successful de novo retrotransposition of L1 and secondly whether miR-128-induced L1 restriction is dependent on reduced hnRNPA1 levels.
We performed colony formation assays using different variants of a neomycin reporter constructs encoding the full length L1 mRNA and a retrotransposition indicator cassette. The WT L1 construct consists of a neomycin gene in the antisense orientation relative to a full-length L1 element, which is disrupted by an intron in the sense orientation.
In order for the neomycin (neo) protein to be translated into a functional enzyme, L1
transcription and splicing of the mRNA, reverse transcription followed by integration of the Finally a third variant of the L1 plasmid described by [62] encodes a L1 RNA containing a D702A mutation in the reverse transcriptase (RT) domain of the ORF2 protein, rendering the encoded L1 RT deficient (RT dead). This plasmid variant was used as a negative control as previously described (Idica et al., in revisions). We generated stable HeLa cell lines overexpressing full length hnRNPA1 or plasmid control, shRNA against hnRNPA1 or a control sequence (GFP, Green Fluorescent Protein). Based on our recent finding that TNPO1
is required for L1 to successfully transpose and that miR-128 targets TNPO1 mRNA for degradation, we also wished to examine the potential additive effect of TNPO1 and hnRNPA1 on L1 retrotransposition, both being miR-128 targets. For this reason we also generated HeLa cell lines stably overexpressing both hnRNPA1 and TNPO1 (hnRNPA1 + TNPO1) and cell lines overexpressing both sh-hnRNPA1 and sh-TNPO1 (sh-hnRNPA1 + and sh-TNPO1). We validated that hnRNPA1 and TNPO1 was regulated as expected in the cell lines (Figure 4 and data now shown) and then initiated colony formation assay analysis.
All hnRNPA1/TNPO1 modulated HeLa cell lines were transfected with the WT L1 or the RT deficient L1 (RT-dead) neomycin reporter and selected for 14 days with neomycin replenished daily. We observed a significant decrease in neomycin resistant colonies in cells overexpressing sh-hnRNPA1, relative to control HeLa cells ( Figure 4A ). Double knockdown (sh-hnRNPA1 and sh-TNPO1) HeLa cells showed further reduced levels of L1 retrotransposition ( Figure 4A ). In contrast, cells overexpressing hnRNPA1 were characterized by a significantly increased number of neo resistant colonies, compared to control HeLa cells ( Figure 4B ). The increase in neo resistant colonies was further increased in hnRNPA1 + TNPO1 double over-expressing cells ( Figure 4B ). Importantly, hnRNPA1
and TNPO1 modulated HeLa cells encoding RT-deficient L1 (RT-dead) resulted in no neomycin-resistant colonies, demonstrating that colonies obtained upon wild-type L1 plasmid transfections and neo selection are the consequence of a round of de novo L1. These experiments demonstrate that hnRNPA1 is required for optimal L1 activity.
miR-128-induced L1 restriction is partly dependent on hnRNPA1.
At this point our findings show that L1-mobolization is dependent on repressing the cellular co-factor hnRNPA1, TNPO1, and direct binding to L1 RNA. In order to evaluate the relative importance of miR-128-induced hnRNPA1 repression we next performed rescue experiments. In brief, we generated miR-128 or miR control HeLa cell lines in which we coexpressed either full lenght hnRNPA1 or plasmid controls. All HeLa cell lines were then transfected with the mutant L1 (miR-128 resistant) plasmid or the RT-dead L1 plasmid as previously described (Idica et al. in revisions). As expected miR-128 significantly reduced L1 retrotransposition as determined by reduced neo resistant colonies ( Figure 5A ). When reintroducing hnRNPA1 into miR-128 over-expressing HeLa cells, we observed a partial, but significant rescue of miR-128 induced L1 restriction ( Figure 5A ), whereas all HeLa cell lines transfected with the RT dead L1 plasmid, resulted in no colonies following neo selection.
Finally, we performed a double rescue experiment using miR control and miR-128
HeLa cells, which overexpressed either plasmid control, full length hnRNPA1, full length TNPO1 or both hnRNPA1 + TNPO1. As observed previously, miR-128 significantly reduced L1 activity, and hnRNPA1 partly rescue the inhibitory effect of miR-128, as compared to control cells ( Figure 5B ). In addition, as previously shown TNPO1 can also partly rescue de novo retrotransposition, and the potency of rescue was further enhanced in cell overexpressing both hnRNPA1 and TNPO1, relative to plasmid control ( Figure 5B 
MATERIALS AND METHODS
Cell culture
All cells were cultured at 37˚C and 5% CO2 and routinely checked for mycoplasma (LT07- 
Transfection and transduction
OptiMem (31985070, Lifetech) and Lipofectamine RNAiMAX (13778075, Lifetech) were used to complex and transfect 20µM miR-128 mimic, anti-miR-128 or control mimics (C-301072-01 and IH-301072-02, Dharmacon) into cells. OptiMem and Xtreme Gene HP (06366236001, Roche Lifescience) was used to transfect pJM101 neomycin L1 reporter plasmid into HeLa cells. Cells were transduced with high titer virus using polybrene (sc-134220, Santa Cruz Biotech) and spinoculation (800xg at 32˚C for 30 minutes). Transduced cells were then selected and maintained using 3µg/mL puromycin.
RNAi using shRNA against hnRNPA1
shRNA for hnRNPA1 was designed using the RNAi Consortium (https://www.broadinstitute.org/rnai/public/) using clone TRCN0000235098 and cloned into pLKO.1 puro backbone (Addgene, #8453). pLKO shGFP control plasmid was pre-assembled (Addgene, #30323).
Lentiviral packaging
VSVG-pseudotyped lentiviral vectors were made by transfecting 0.67µg of pMD2-G (12259, Addgene), 1.297µg of pCMV-DR8.74 (8455, Addgene), and 2µg of mZIP-miR-128, mZIPanti-miR-128, pLKO-shControl or pLKO-shHNRNPA1 (transfer plasmid)) into 293T cells using Lipofectamine LTX with plus reagent (15338030, ThermoFisher). Virus-containing supernatant was collected 48hr and 96hr post-transfection. Viral SUPs were concentrated using PEG-it virus precipitation solution (LV810A-1) according to manufacturer's instructions.
RNA extraction and quantification
RNA was extracted using Trizol (15596-018, ThermoFisher) and Direct-zol RNA isolation kit (R2070, Zymo Research). cDNA was made with High-Capacity cDNA Reverse
Transcription Kit (4368813, ThermoFisher). Amount of hnRNPA1 mRNA was analyzed by qRT-PCR (Sense primer 5'-aagcaattttggaggtggtg-3'; Antisense primer 5'-atagccaccttggtttcgtg-3') using Forget-me-not qPCR mastermix (Biotium) relative to beta-2-microglobulin (B2m, Sense primer 5'-ATGTCTCGCTCCGTGGCCTTAGCT-3'; Antisense primer 5'-TGGTTCACACGGCAGGCATACTCAT-3') housekeeping gene and processed using the ΔΔC t method.
Western blotting
Rabbit anti-human hnRNPA1 antibody (K350, Cell Signaling Technology) was used at 1:2000. Anti-alpha Tubulin antibody (ab4074, Abcam) was diluted 1:5000 and used as a loading control, validation of antibodies can be found on the manufacturer websites.
Secondary HRP-conjugated anti-rat (ab102172, Abcam) or HRP-conjugated anti-rabbit (#NA934, GE lifesciences) were used at 1:5000. ECL substrate (32106, ThermoFisher) was added and visualized on a BioRad ChemiDoc imager.
Argonaute-RNA immuno-purification
Immunopurification of Argonaute from HeLa cell extracts was performed using the 4F9 antibody (#sc-53521, Santa Cruz Biotechnology) as described previously [72, 73] . Briefly, 
Cloning
To generate the hnRNPA1 and TNPO1 full-length clones we modified the plasmid pFC-PGK-MCS-pA-EF1-GFP-T2A-Puro (SBI, backbone) by replacing the PGK with a CMV promoter. The CMV promoter provides a strong and robust expression on most cell types.
The CMV promoter was amplified by PCR from the phiC31 integrase expression plasmid (SBI). To generate the CMV promoter insert, we used the sense CMV primer (5´-CTAGAACTAG TTATTAATAG TAATCAATTA CGGGGTC-3´) and antisense CMV primer (5´-GATATCGGAT CCACCGGTAC CAAGCTTAAG TTTAAAC-3´). The insert and the backbone of the plasmid were cut by XbaI and BamHI and purified by an agarose gel.
Insert and backbone were ligated together using the quick ligation kit (NEB) and transformed. The resulting plasmid pFC-CMV-MCS-pA-EF-1-GFP-T2A-Puro-MH1 was verified by sequencing.
For the cloning of the full-length hnRNPA1 and TNPO1 mRNA expression clone, we isolated total RNA from HeLa cells. 20 ng of the total RNA was reverse transcribed using a poly dT primer. All amplicons were generated using the Phusion High-Fidelity PCR Kit 
Site directed mutagenesis
Reverse transcriptase incompetent PJM101/L1 plasmid was made using Q5 Site-directed mutagenesis Kit (E0554S, New England Biolabs) and mutation strategy described in Morrish et al. where D702A mutation in L1 ORF2 resulted in an incompetent reverse transcriptase, called RT-dead L1.
Colony formation assay
Stable HeLa lines expressing miR-128, anti-miR-128, scramble control, shControl, shhnRNPA1, shTNPO1, Full length hnRNPA1 or TNPO1, or plasmid control were transfected with pJM101/L1RP or RT-dead L1 plasmid (containing neomycin resistance retrotransposition indicator cassette) per well using X-treme gene HP DNA transfection reagent (06366236001, Roche) according to manufacturer instructions. Cells were selected using 500µg/mL G418 (ant-gn-1, Invivogen). Neomycin-resistant colonies were fixed with cold 1:1 methanol:acetone then visualized using May-Grunwald (ES-3410, Fisher Sci) and
Jenner-Giemsa staining kits (ES-8150, Fisher Sci) according to manufacturer protocol. Stable iPSC lines expressing miR-128, anti-miR-128 or scramble control were transfected with pJM101/L1RP using Xtreme gene HP DNA transfection reagent according to manufacturer instructions. Selection began with 25 µg/mL G418 72hr post-transfection and selection was maintained with daily media changes until negative control (non-transfected) cells died.
Neomycin-resistant colonies were fixed as described above.
RNA sequencing and data analysis
DGCR8
-/-mESCs were transfected with miR controls or miR-128 in triplicate cultures and harvested cells after 12hours in order to enrich for primary target mRNAs, as opposed to studying secondary effects of miR-128. Two replicates of each triplicate were selected and cDNA libraries were generated using the Smart-seq2 protocol [57] . The libraries were sequenced as 43 bp paired-end reads. STAR [58] was used to align the reads on to the mm9 genome. RSEM [59] was used to quantitate the gene expression and EBSeq [60] was used to identify differentially expressed genes. 
